Učitavanje...
Potential role of immunotherapy in advanced non-small-cell lung cancer
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymph...
Spremljeno u:
| Izdano u: | Onco Targets Ther |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5179204/ https://ncbi.nlm.nih.gov/pubmed/28031719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S90459 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|